Apogee Therapeutics Inc (APGE)
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
📈 **POSITIVE** • Medium confidence analysis (64%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (79%) **Content type:** Clinical